Cytosorbents Corporation develops blood purification technologies for life-threatening conditions in intensive care and cardiac surgery. Its lead product, CytoSorb®, is approved in the European Union, distributed internationally, and used for cytokine adsorption and CE-marked applications that include bilirubin, myoglobin, ticagrelor, and rivaroxaban removal; in the United States it has FDA Emergency Use Authorization for adult critically ill COVID-19 patients with respiratory failure and is not otherwise approved or cleared.
Company updates commonly address quarterly and annual results, gross margin and balance-sheet actions, product launches such as HotSwap™, distribution partnerships, clinical evidence for CytoSorb therapy, and regulatory work around the investigational DrugSorb®-ATR antithrombotic removal system. The product portfolio also includes ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, ContrastSorb, PuriFi®, and related blood purification technologies.
CytoSorbents Corporation (NASDAQ: CTSO) has announced the commercial launch of its CytoSorb blood purification technology in nine Latin American countries, including Colombia, Argentina, and Peru, amidst rising COVID-19 cases. The product helps treat dangerous inflammation in critically-ill patients and is now available in 65 countries globally. The launch is timely; Latin America reports over 2.1 million COVID-19 cases and a mortality rate of 4.6%. With the ongoing pandemic, CytoSorb is expected to play a crucial role in addressing cytokine storm complications in COVID-19 patients.